Wetherby Asset Management Inc Seagen Inc. Transaction History

Wetherby Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $38,876 - $43,880	203 Added 8.57%	2,571 $545,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $52,163 - $57,337	-278 Reduced 10.51%	2,368 $455,000
Q1 2023 May 12, 2023	BUY	$127.59 - $203.08 $64,177 - $102,149	503 Added 23.47%	2,646 $535,000
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $45,539 - $53,997	388 Added 22.11%	2,143 $275,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $6,087 - $8,104	-45 Reduced 2.5%	1,755 $240,000
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $27,637 - $45,549	254 Added 16.43%	1,800 $318,000
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $33,849 - $44,671	-283 Reduced 15.47%	1,546 $223,000
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $15,540 - $20,803	-109 Reduced 5.62%	1,829 $283,000
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $8,404 - $10,019	59 Added 3.14%	1,938 $329,000
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $11,481 - $13,693	85 Added 4.74%	1,879 $297,000
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $27,777 - $38,541	-202 Reduced 10.12%	1,794 $249,000
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $328,601 - $423,012	1,996 New	1,996 $350,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.